Pathophysiology and treatment options for cardiac anorexia

Current Heart Failure Reports

Volumn 8, Issue 2, 2011, Pages 147-153

  Fudim, Marat ^a   Wagman, Gabriel ^b   Altschul, Rebecca ^c   Yucel, Evin ^d   Bloom, Michelle ^b   Vittorio, Timothy J ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Anorexia; Cachexia; Chronic heart failure; Neurohormonal

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GHRELIN; INTERLEUKIN 6; LEPTIN; MEGESTROL ACETATE; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; NEUROHORMONE; PENTOXIFYLLINE; PROOPIOMELANOCORTIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; ARTICLE; CACHEXIA; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; HUMAN; INFLAMMATION; NONHUMAN; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; REGULATORY MECHANISM; UNSPECIFIED SIDE EFFECT;

ANOREXIA; HEART FAILURE; HUMANS;

EID: 79957516454     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0049-5     Document Type: Article

References (87)

1. DM Lloyd-Jones MG Larson EP Leip, et al. 2002 Lifetime risk for developing congestive heart failure: the Framingham Heart Study Circulation 106 3068 3072 12473553 10.1161/01.CIR.0000039105.49749.6F (Pubitemid 35440290)
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation [serial on the Internet]. 2007;115(5): Available at http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=17194875; http://circ.ahajournals.org/cgi/reprint/115/5/e69.pdf.
3. VL Roger SA Weston MM Redfield, et al. 2004 Trends in heart failure incidence and survival in a community-based population JAMA 292 3 344 350 15265849 10.1001/jama.292.3.344 1:CAS:528:DC%2BD2cXlvFaju7k%3D (Pubitemid 38944258)
4. GS Bleumink AM Knetsch MC Sturkenboom, et al. 2004 Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study Eur Heart J 25 18 1614 1619 15351160 10.1016/j.ehj.2004.06.038 (Pubitemid 39209281)
5. NA Stephens KCH Fearon 2008 Anorexia, cachexia and nutrition Medicine 36 2 78 81 10.1016/j.mpmed.2007.11.004 (Pubitemid 351164237)
6. S von Haehling M Lainscak J Springer, et al. 2009 Cardiac cachexia: a systematic overview Pharmacol Ther 121 3 227 252 10.1016/j.pharmthera.2008.09. 009 This extensive article reviews the complex pathophysiology of cardiac cachexia and CHF, with particular focus on immunological, metabolic, and hormonal aspects
7. M Muscaritoli SD Anker J Argiles, et al. 2010 Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics" Clin Nutr 29 2 154 159 20060626 10.1016/j.clnu.2009.12.004 1:STN:280:DC%2BC3c3isFOltA%3D%3D
8. M Maltoni M Pirovano E Scarpi, et al. 1995 Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study Cancer 75 10 2613 2622 7537625 10.1002/1097-0142(19950515)75: 10<2613::AID-CNCR2820751032>3.0.CO;2-1 1:STN:280:DyaK2M3lsVCmtg%3D%3D
9. K Kalantar-Zadeh G Block CJ McAllister, et al. 2004 Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients Am J Clin Nutr 80 2 299 307 15277149 1:CAS:528:DC%2BD2cXmtFKju7g%3D (Pubitemid 41080002)
10. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet [serial on the Internet]. 1997;349(9058): Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=9107242.
11. SD Anker JW Swan M Volterrani, et al. 1997 The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure Eur Heart J 18 2 259 269 9043843 1:STN:280:DyaK2s7ps1Omtg%3D%3D (Pubitemid 27107588)
12. LM Freeman 2009 The pathophysiology of cardiac cachexia Curr Opin Support Palliat Care 3 4 276 281 19797959 10.1097/SPC.0b013e32833237f1
13. D King ML Smith TJ Chapman, et al. 1996 Fat malabsorption in elderly patients with cardiac cachexia Age Ageing 25 2 144 149 8670544 10.1093/ageing/25.2.144 1:STN:280:DyaK283mvVylsQ%3D%3D (Pubitemid 26091169)
14. KK Witte AL Clark 2006 Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives Heart Fail Rev 11 1 65 74 16819579 10.1007/s10741-006-9194-4 1:CAS:528:DC%2BD28XmsFCisrg%3D (Pubitemid 43986209)
15. GP Arutyunov OI Kostyukevich RA Serov, et al. 2008 Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure Int J Cardiol 125 2 240 245 18242735 10.1016/j.ijcard. 2007.11.103
16. A Sandek W Doehner SD Anker, et al. 2009 Nutrition in heart failure: an update Curr Opin Clin Nutr Metab Care 12 4 384 391 19474718 10.1097/MCO. 0b013e32832cdb0f This review highlights the current knowledge of nutritional abnormalities that may occur in CHF. Furthermore, the article discusses the regulation of feeding and nutritional strategies as supportive treatment options of CHF
17. K Kalantar-Zadeh SD Anker TB Horwich, et al. 2008 Nutritional and anti-inflammatory interventions in chronic heart failure Am J Cardiol 101 11A 89E 103E 18514634 10.1016/j.amjcard.2008.03.007 1:CAS:528:DC%2BD1cXotlCqtrY%3D
18. TB Horwich K Kalantar-Zadeh RW MacLellan, et al. 2008 Albumin levels predict survival in patients with systolic heart failure Am Heart J 155 5 883 889 18440336 10.1016/j.ahj.2007.11.043 1:CAS:528:DC%2BD1cXlsFCht7s%3D
19. V Soukoulis JB Dihu M Sole, et al. 2009 Micronutrient deficiencies an unmet need in heart failure J Am Coll Cardiol 54 18 1660 1673 19850206 10.1016/j.jacc.2009.08.012 1:CAS:528:DC%2BD1MXhsFait7rM
20. MJ Tisdale 2009 Mechanisms of cancer cachexia Physiol Rev 89 2 381 410 19342610 10.1152/physrev.00016.2008 1:CAS:528:DC%2BD1MXkvFegu74%3D
21. A Inui 2002 Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52 2 72 91 11929007 10.3322/canjclin.52.2.72 (Pubitemid 34256834)
22. I Lesman-Leegte T Jaarsma R Sanderman 2006 Depressive symptoms are prominent among elderly hospitalised heart failure patients Eur J Heart Fail 8 6 634 640 16504577 10.1016/j.ejheart.2005.11.010 (Pubitemid 44572957)
23. WJ Evans JE Morley J Argiles, et al. 2008 Cachexia: a new definition Clin Nutr 27 6 793 799 18718696 10.1016/j.clnu.2008.06.013 1:CAS:528: DC%2BD1cXhsVWrsbzI
24. MD Deboer 2009 Animal models of anorexia and cachexia Expert Opin Drug Discov 4 11 1145 1155 20160874 10.1517/17460440903300842
25. A Laviano MM Meguid F Rossi-Fanelli 2003 Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies Lancet Oncol 4 11 686 694 14602249 10.1016/S1470-2045(03)01247-6 1:CAS:528:DC%2BD3sXos1Kjtb0%3D (Pubitemid 37407436)
26. A Laviano A Inui DL Marks, et al. 2008 Neural control of the anorexia-cachexia syndrome Am J Physiol Endocrinol Metab 295 5 E1000 E1008 18713954 10.1152/ajpendo.90252.2008 1:CAS:528:DC%2BD1cXhsVWkurbJ This article takes a close look at the role of hypothalamic pathways in the pathogenesis of anorexia
27. RD Cone 2005 Anatomy and regulation of the central melanocortin system Nat Neurosci 8 5 571 578 15856065 10.1038/nn1455 1:CAS:528:DC%2BD2MXjsFyktbo%3D (Pubitemid 40594196)
28. NA Tritos D Vicent J Gillette, et al. 1998 Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus Diabetes 47 11 1687 1692 9792536 10.2337/diabetes.47.11.1687 1:CAS:528:DyaK1cXntVSjsrw%3D (Pubitemid 28476241)
29. Scarlett J, Bowe D, Batra A, et al. Genetic and Pharmacologic Blockade of Central Melanocortin Signaling Attenuates Cardiac Cachexia in Rodent Models of Heart Failure. J Endocrinol. 2010.
30. T Kung J Springer W Doehner, et al. 2010 Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference Expert Opin Investig Drugs 19 4 579 585 20367196 10.1517/13543781003724690 1:CAS:528:DC%2BC3cXkt1agtbw%3D
31. H Krude H Biebermann W Luck, et al. 1998 Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans Nat Genet 19 2 155 157 9620771 10.1038/509 1:CAS:528:DyaK1cXls1Crt7o%3D (Pubitemid 28248796)
32. GS Yeo IS Farooqi S Aminian, et al. 1998 A frameshift mutation in MC4R associated with dominantly inherited human obesity Nat Genet 20 2 111 112 9771698 10.1038/2404 1:CAS:528:DyaK1cXms1amsLw%3D (Pubitemid 28455438)
33. MA Joppa KR Gogas AC Foster, et al. 2007 Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice Peptides 28 3 636 642 17204351 10.1016/j.peptides.2006.11.021 1:CAS:528:DC%2BD2sXhs1Cjsbg%3D (Pubitemid 46205015)
34. A Jatoi CL Loprinzi JA Sloan, et al. 2001 Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation Cancer 92 3 629 633 11505408 10.1002/1097-0142(20010801)92:3<629::AID-CNCR1363>3.0.CO;2-M 1:CAS:528:DC%2BD3MXmsVyjtLY%3D (Pubitemid 32735199)
35. CM Edwards S Abusnana D Sunter, et al. 1999 The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin J Endocrinol 160 3 R7 R12 10077743 10.1677/joe.0.160R007 1:CAS:528:DyaK1MXktVeqtrk%3D
36. AS Maisel NA Scott HJ Motulsky, et al. 1989 Elevation of plasma neuropeptide Y levels in congestive heart failure Am J Med 86 1 43 48 2910096 10.1016/0002-9343(89)90228-3 1:STN:280:DyaL1M%2Fos1Cltg%3D%3D (Pubitemid 19039536)
37. SC Woods DA D'Alessio 2008 Central control of body weight and appetite J Clin Endocrinol Metab 93 11 Suppl 1 S37 S50 18987269 10.1210/jc.2008-1630 1:CAS:528:DC%2BD1cXhtlOqurrJ This article reviews our knowledge on the influence of hormonal signals on food intake and their clinical significance
38. JE Morley SA Farr 2008 Cachexia and neuropeptide Y Nutrition 24 9 815 819 18725077 10.1016/j.nut.2008.06.020 1:CAS:528:DC%2BD1cXhtVent73K
39. M Kojima H Hosoda Y Date, et al. 1999 Ghrelin is a growth-hormone- releasing acylated peptide from stomach Nature 402 6762 656 660 10604470 10.1038/45230 1:CAS:528:DC%2BD3cXjs1Ki (Pubitemid 129516334)
40. AM Wren LJ Seal MA Cohen, et al. 2001 Ghrelin enhances appetite and increases food intake in humans J Clin Endocrinol Metab 86 12 5992 11739476 10.1210/jc.86.12.5992 1:CAS:528:DC%2BD3MXptVyksLg%3D (Pubitemid 33152655)
41. JM Garcia WJ Polvino 2007 Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers Oncologist 12 5 594 600 17522248 10.1634/theoncologist.12-5-594 1:CAS:528:DC%2BD2sXntVynsL4%3D (Pubitemid 350012123)
42. MR Druce AM Wren AJ Park, et al. 2005 Ghrelin increases food intake in obese as well as lean subjects Int J Obes Lond 29 9 1130 1136 15917842 10.1038/sj.ijo.0803001 1:CAS:528:DC%2BD2MXnt1Sht7s%3D (Pubitemid 41192222)
43. K Lundholm L Gunnebo U Korner, et al. 2010 Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study Cancer 116 8 2044 2052 20186829 10.1002/cncr.24917 1:CAS:528:DC%2BC3cXlvVGltrk%3D
44. E Arvat L Di Vito F Broglio, et al. 2000 Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans J Endocrinol Investig 23 8 493 495 1:CAS:528: DC%2BD3cXnt1Kmurw%3D
45. Y Sun P Wang H Zheng, et al. 2004 Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor Proc Natl Acad Sci USA 101 13 4679 4684 15070777 10.1073/pnas. 0305930101 1:CAS:528:DC%2BD2cXjtFKisb0%3D (Pubitemid 38437470)
46. GJ Morton DE Cummings DG Baskin, et al. 2006 Central nervous system control of food intake and body weight Nature 443 7109 289 295 16988703 10.1038/nature05026 1:CAS:528:DC%2BD28Xpslalu7c%3D (Pubitemid 44435142)
47. HY Chen ME Trumbauer AS Chen, et al. 2004 Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein Endocrinology 145 6 2607 2612 14962995 10.1210/en.2003-1596 1:CAS:528:DC%2BD2cXkt12gt7k%3D (Pubitemid 38686204)
48. MD DeBoer XX Zhu P Levasseur, et al. 2007 Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia Endocrinology 148 6 3004 3012 17347304 10.1210/en.2007-0016 1:CAS:528:DC%2BD2sXmt1aju74%3D (Pubitemid 46984811)
49. N Nagaya M Uematsu M Kojima, et al. 2001 Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors Circulation 104 17 2034 2038 11673342 10.1161/hc4201.097836 1:CAS:528:DC%2BD3MXosFOqu7c%3D (Pubitemid 33027043)
50. N Nagaya M Uematsu M Kojima, et al. 2001 Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure Circulation 104 12 1430 1435 11560861 10.1161/hc3601.095575 1:CAS:528:DC%2BD3MXnslCltbw%3D (Pubitemid 32880158)
51. XB Xu JJ Pang JM Cao, et al. 2005 GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure Am J Physiol Heart Circ Physiol 289 4 H1643 H1651 15951341 10.1152/ajpheart.01042.2004 1:CAS:528:DC%2BD2MXhtFensLbP (Pubitemid 41369008)
52. N Nagaya J Moriya Y Yasumura, et al. 2004 Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure Circulation 110 24 3674 3679 15569841 10.1161/01.CIR.0000149746.62908.BB 1:CAS:528:DC%2BD2cXhtVCisbvI (Pubitemid 39665256)
53. J Ashitani N Matsumoto M Nakazato 2009 Ghrelin and its therapeutic potential for cachectic patients Peptides 30 10 1951 1956 19595727 10.1016/j.peptides.2009.07.002 1:CAS:528:DC%2BD1MXhtFyqt7zO
54. VD Dixit EM Schaffer RS Pyle, et al. 2004 Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells J Clin Invest 114 1 57 66 15232612 1:CAS:528:DC%2BD2cXls1altLo%3D (Pubitemid 39071644)
55. Q Xia W Pang H Pan, et al. 2004 Effects of ghrelin on the proliferation and secretion of splenic T lymphocytes in mice Regul Pept 122 3 173 178 15491788 10.1016/j.regpep.2004.06.016 1:CAS:528:DC%2BD2cXos1eiu7g%3D (Pubitemid 39371166)
56. T Ronti G Lupattelli E Mannarino 2006 The endocrine function of adipose tissue: an update Clin Endocrinol 64 4 355 365 1:CAS:528:DC%2BD28XkslSrtbc%3D
57. W Doehner CD Pflaum M Rauchhaus, et al. 2001 Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia Eur J Endocrinol 145 6 727 735 11720897 10.1530/eje.0.1450727 1:CAS:528:DC%2BD3MXpt1Ght7k%3D (Pubitemid 33133679)
58. GS Filippatos K Tsilias K Venetsanou, et al. 2000 Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system Int J Cardiol 76 2-3 117 122 11104865 10.1016/S0167-5273(00)00397-1 1:STN:280:DC%2BD3M7ktlymtg%3D%3D
59. EM El-Bindary AZ Darwish 2001 New biochemical markers in chronic heart failure East Mediterr Health J 7 4-5 697 706 15332768 1:STN:280: DC%2BD2cvislCqtQ%3D%3D
60. F Leyva SD Anker K Egerer, et al. 1998 Hyperleptinaemia in chronic heart failure. Relationships with insulin Eur Heart J. 19 10 1547 1551 9820994 10.1053/euhj.1998.1045 1:STN:280:DyaK1M%2FjvVCgtw%3D%3D (Pubitemid 28470477)
61. W Doehner M Rauchhaus IF Godsland, et al. 2002 Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha Int J Cardiol 83 1 73 81 11959387 10.1016/S0167-5273(02)00022-0 (Pubitemid 34311881)
62. LH Tecott 2007 Serotonin and the orchestration of energy balance Cell Metab 6 5 352 361 17983581 10.1016/j.cmet.2007.09.012 1:CAS:528: DC%2BD2sXhtlemsr%2FI (Pubitemid 350012001)
63. LK Heisler EE Jobst GM Sutton, et al. 2006 Serotonin reciprocally regulates melanocortin neurons to modulate food intake Neuron 51 2 239 249 16846858 10.1016/j.neuron.2006.06.004 1:CAS:528:DC%2BD28XotVCjtbs%3D (Pubitemid 44063615)
64. SD Anker S von Haehling 2004 Inflammatory mediators in chronic heart failure: an overview Heart 90 4 464 470 15020532 10.1136/hrt.2002.007005 1:CAS:528:DC%2BD2cXjs1agtLk%3D (Pubitemid 38406929)
65. SD Anker KR Egerer HD Volk, et al. 1997 Elevated soluble CD14 receptors and altered cytokines in chronic heart failure Am J Cardiol 79 10 1426 1430 9165177 10.1016/S0002-9149(97)00159-8 1:STN:280:DyaK2szgslygtw%3D%3D (Pubitemid 27262079)
66. R Sharma AP Bolger M Rauchhaus, et al. 2005 Cellular endotoxin desensitization in patients with severe chronic heart failure Eur J Heart Fail 7 5 865 868 16087139 10.1016/j.ejheart.2004.09.014 1:CAS:528:DC%2BD2MXns1Wltrg%3D (Pubitemid 41125907)
67. J Niebauer HD Volk M Kemp, et al. 1999 Endotoxin and immune activation in chronic heart failure: a prospective cohort study Lancet 353 9167 1838 1842 10359409 10.1016/S0140-6736(98)09286-1 1:STN:280:DyaK1M3osF2nsA%3D%3D (Pubitemid 29251016)
68. A Sandek J Bauditz A Swidsinski, et al. 2007 Altered intestinal function in patients with chronic heart failure J Am Coll Cardiol 50 16 1561 1569 17936155 10.1016/j.jacc.2007.07.016 1:CAS:528:DC%2BD2sXhtFKisLnF (Pubitemid 47532323)
69. Y Ueta H Hashimoto E Onuma, et al. 2007 Hypothalamic neuropeptides and appetite response in anorexia-cachexia animal Endocr J 54 6 831 838 17827790 10.1507/endocrj.KR-111 (Pubitemid 351346764)
70. SS Yeh K Blackwood MW Schuster 2008 The cytokine basis of cachexia and its treatment: are they ready for prime time? J Am Med Dir Assoc 9 4 219 236 18457797 10.1016/j.jamda.2008.01.003 (Pubitemid 351598056)
71. JB Buchanan RW Johnson 2007 Regulation of food intake by inflammatory cytokines in the brain Neuroendocrinology 86 3 183 190 17823502 10.1159/000108280 1:CAS:528:DC%2BD2sXht1Kjtr%2FM (Pubitemid 350073606)
72. M Ek M Kurosawa T Lundeberg, et al. 1998 Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins J Neurosci 18 22 9471 9479 9801384 1:CAS:528:DyaK1cXnsVKns7k%3D (Pubitemid 28512476)
73. MD DeBoer 2010 Update on melanocortin interventions for cachexia: progress toward clinical application Nutrition 26 2 146 151 20004082 10.1016/j.nut.2009.07.003 1:CAS:528:DC%2BC3cXjvVerug%3D%3D This report describes the pathophysiologic role of melanocortin in anorexia-cachexia syndrome and provides evidence for the efficacy of melanocortin antagonists
74. JM Scarlett EE Jobst PJ Enriori, et al. 2007 Regulation of central melanocortin signaling by interleukin-1 beta Endocrinology 148 9 4217 4225 17525125 10.1210/en.2007-0017 1:CAS:528:DC%2BD2sXpslCntLo%3D (Pubitemid 47295678)
75. R Janoschek L Plum L Koch, et al. 2006 gp130 signaling in proopiomelanocortin neurons mediates the acute anorectic response to centrally applied ciliary neurotrophic factor Proc Natl Acad Sci USA 103 28 10707 10712 16818888 10.1073/pnas.0600425103 1:CAS:528:DC%2BD28XntFWmsLY%3D (Pubitemid 44078041)
76. TM Reyes PE Sawchenko 2002 Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia J Neurosci 22 12 5091 5099 12077204 1:CAS:528:DC%2BD38Xlt1Sgsb8%3D (Pubitemid 37465622)
77. CR Plata-Salaman 1994 Meal patterns in response to the intracerebroventricular administration of interleukin-1 beta in rats Physiol Behav 55 4 727 733 8190802 10.1016/0031-9384(94)90052-3 1:CAS:528: DyaK2cXisVahsL8%3D (Pubitemid 24104403)
78. P Sarraf RC Frederich EM Turner, et al. 1997 Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia J Exp Med 185 1 171 175 8996253 10.1084/jem.185.1.171 1:CAS:528: DyaK2sXjvF2rsg%3D%3D (Pubitemid 27039451)
79. K Hryniewicz AS Androne A Hudaihed SD Katz 2003 Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure J Card Fail 9 6 464 468 14966787 10.1016/S1071-9164(03)00582-7 1:CAS:528:DC%2BD3sXhtVShs77F (Pubitemid 38055655)
80. SD Anker A Negassa AJ Coats, et al. 2003 Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study Lancet 361 9363 1077 1083 12672310 10.1016/S0140-6736(03)12892-9 1:CAS:528:DC%2BD3sXisFSntL4%3D (Pubitemid 36369559)
81. BT Steffen SJ Lees FW Booth 2008 Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia J Appl Physiol 105 6 1950 1958 18801959 10.1152/japplphysiol.90884.2008 1:CAS:528: DC%2BD1MXmvFSltg%3D%3D
82. S Shaw M Shah S Williams 2009 Immunological mechanisms of pentoxifylline in chronic heart failure Eur J Heart Fail 11 113 118 19168508 10.1093/eurjhf/hfn040 1:CAS:528:DC%2BD1MXjvFOrtrs%3D
83. DS Silverberg D Wexler A Iaina, et al. 2009 Immunological mechanisms of pentoxifylline in chronic heart failure Eur J Heart Fail 11 7 728 19457899 10.1093/eurjhf/hfp067
84. H Butler M Korbonits 2009 Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists Eur J Endocrinol 161 5 655 662 19729432 10.1530/EJE-09-0511 1:CAS:528:DC%2BD1MXhsFajt7bL
85. D Turcotte JA Le Dorze F Esfahani, et al. 2010 Examining the roles of cannabinoids in pain and other therapeutic indications: a review Expert Opin Pharmacother 11 1 17 31 20001426 10.1517/14656560903413534 1:CAS:528: DC%2BD1MXhsFCitLvP
86. KM Gamber H Macarthur TC Westfall 2005 Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus Neuropharmacology 49 5 646 652 15949823 1:CAS:528:DC%2BD2MXpslCnu7Y%3D (Pubitemid 41208286)
87. F Facchinetti E Del Giudice S Furegato, et al. 2003 Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide Glia 41 2 161 168 12509806 10.1002/glia.10177 (Pubitemid 36262193)